Rare Diseases Report 2022

The broad and challenging – but promising – landscape of peripheral neuropathy


 

Therapeutic options

There are no FDA-approved treatments for CSPN, as most treatments are geared toward neuropathic pain management, rehabilitation, and supportive care.68 Due to a lack of research and data regarding these types of peripheral neuropathies, various studies suggest different first-line therapies. For example, anticonvulsants (pregabalin, gabapentin), antidepressants (duloxetine), and opioid-like compounds (tramadol) are all threapy options to treat DPN.3

Adequate data are lacking to support the efficacy of immunosuppressive therapy in CSPN.

Pages

Recommended Reading

Inebilizumab beneficial across genotypes in NMOSD
MDedge Neurology
Tofersen linked to slow, positive effects in ALS
MDedge Neurology
FDA unveils 5-year plan for ALS and other neurodegenerative diseases
MDedge Neurology
First-ever Huntington staging system may jump-start drug development for early-stage disease
MDedge Neurology
Two deaths from liver failure linked to spinal muscular atrophy drug
MDedge Neurology
Polio: The unwanted sequel
MDedge Neurology
CDC warns of enterovirus strain linked to polio-like condition
MDedge Neurology
Ketamine promising for rare condition linked to autism
MDedge Neurology
ALS drug gets FDA panel thumbs-up after rare second look
MDedge Neurology
Myasthenia gravis: Finding strength in treatment options
MDedge Neurology